(Q38099392)

28 August 2017

title

Molecularly targeted therapies for melanoma (English)

1 reference

28 August 2017

Lucinda S Liu

1

1 reference

28 August 2017

Oscar R Colegio

series ordinal

2

1 reference

28 August 2017

publication date

1 May 2013

1 reference

International Journal of Dermatology

28 August 2017

published in

1 reference

28 August 2017

volume

52

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

523-530

1 reference

Rene Theophile Hyacinthe Laënnec (1781-1826): the man behind the stethoscope

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Early accelerated approval for highly targeted cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Vemurafenib for melanoma metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Sorafenib-induced premalignant and malignant skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Signal transduction via the stem cell factor receptor/c-Kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Cytotoxic T-lymphocyte-associated antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Hemophilia A induced by ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05829.X

10.1111/J.1365-4632.2012.05829.X

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference